Literature DB >> 23329190

Development, characterization and clinical validation of new sensitive immunofluorometric assay for the measurement of serum thyroglobulin.

Cláudia C D Nakabashi1, Rosa Paula M Biscolla, Teresa S Kasamatsu, Teresinha T Tachibana, Rafaela N Barcelos, Eduardo Z Malouf, Danielle M Andreoni, Rui M B Maciel, José Gilberto H Vieira.   

Abstract

OBJECTIVE: In the last decade, data published stressed the role of highly-sensitive thyroglobulin (Tg) assays in the follow-up of differentiated thyroid carcinoma (DTC) patients. The present study describes a new, highly-sensitive Tg assay, compares it with an available commercial assay, and validates it in the follow-up of DTC patients. SUBJECTS AND METHODS: The immunofluorometric high-sensitivity Tg assay is based on monoclonal and polyclonal antibodies produced at our laboratories. It was validated in 100 samples of 87 patients with DTC submitted to total thyroidectomy, 87% of whom also received radioiodine. For correlation, all samples were also tested using a commercial Tg assay (Beckman Access) with functional sensitivity (FS) of 0.1 ng/mL.
RESULTS: The new method showed FS of 0.3 ng/mL. The correlation between the two methods was good (r = 0.74; p < 0.0001). The diagnostic sensitivity was 88.9%, and it was increased to 100% when combined with neck US.
CONCLUSION: This new, high-sensitivity Tg assay presented a good correlation with Beckman Access assay and with the clinical outcome of the patients. The continuous availability of a validated assay is an additional advantage for long term follow-up of DTC patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23329190     DOI: 10.1590/s0004-27302012000900010

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  2 in total

1.  Basal serum thyroglobulin measured by a second-generation assay is equivalent to stimulated thyroglobulin in identifying metastases in patients with differentiated thyroid cancer with low or intermediate risk of recurrence.

Authors:  Cláudia C D Nakabashi; Teresa S Kasamatsu; Felipe Crispim; Claudia A Yamazaki; Cléber P Camacho; Danielle M Andreoni; Rosalia P Padovani; Elza S Ikejiri; Maria C O M Mamone; Flávia C Aldighieri; Jairo Wagner; Jairo T Hidal; José G H Vieira; Rosa P M Biscolla; Rui M B Maciel
Journal:  Eur Thyroid J       Date:  2014-03-12

Review 2.  How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.

Authors:  Carole Spencer; Jonathan LoPresti; Shireen Fatemi
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.